Concepedia

Author

Alexa B. Schrock

Foundation Medicine (United States)ORCID

Also Known As

A B Schrock, A Schröck, A. Schrock, A. Schröck, A.B. Schrock, Alexa B Schrock, Alexa B. Schrock, Alexa Betzig Schrock, Alexa Schrock, Alexa B. Schrock

808

Publications

16.9K

Citations

58

H-Index

55

Concepts

All Affiliations

Foundation Medicine (United States)Albany Medical Center HospitalSUNY Upstate Medical UniversityUniversity of California, IrvineThe University of Texas MD Anderson Cancer Center
AB

About

Alexa B. Schrock is an author at Foundation Medicine (United States) specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

42

2.8K

2

Health Sciences

11

11

709

3

Cell Biology

10

10

940

4

Engineering

4

4

488

5

Chemistry

1

1

39

Alexa B. Schrock

×

140

Publications

15.7K

Citations

57

H-Index

YearCitations

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers, Caitlin Connelly, David Fabrizio,

Genome Medicine

2017

3.6K

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt,

Cancer Discovery

2018

1.5K

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

Alexa B. Schrock, Ching Ouyang, Jaideep Sandhu,

Annals of Oncology

2019

616

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R.S.K. Vijayan,

Nature

2021

416

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

Alexa B. Schrock, Garrett M. Frampton, James Suh,

Journal of Thoracic Oncology

2016

370

<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer

Jeremy Jones, Lindsay A. Renfro, Humaid O. Al‐Shamsi,

Journal of Clinical Oncology

2017

352

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

Aatur D. Singhi, Ben George, Joel Greenbowe,

Gastroenterology

2019

329

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B. Schrock,

JNCI Journal of the National Cancer Institute

2017

322

Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i>-Positive Lung Cancer

Viola W. Zhu, Satoshi Yoda, Beow Y. Yeap,

Journal of Clinical Oncology

2018

313

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures

Adrienne Johnson, Eric A. Severson, Laurie M. Gay,

The Oncologist

2017

268

Page 1